Oppenheimer downgrades Ventyx to perform, removes price target (VTYX)
IvelinRadkov Oppenheimer downgraded its rating of Ventyx Biosciences (NASDAQ:VTYX) to perform, citing the company’s decision to discontinue development of its drug VTX958 for plaque psoriasis and psoriatic arthritis due to disappointing…
